跳至主要内容
临床试验/EUCTR2014-000562-21-NL
EUCTR2014-000562-21-NL进行中(未招募)不适用

Amyloid-PET as a diagnostic marker in daily practice.

VU University Medical Center0 个研究点开始时间: 2015年1月5日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients of the VUmc Alzheimer Center with a written informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 150
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 350

排除标准

  • Patients who
  • - are considered medically unstable (assessed by physician);
  • - require additional laboratory tests or workup between enrollment and completion of the [18F]FBB PET scan;
  • - are females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception. Females of childbearing potential must not be pregnant or breast feeding at screening. Females must avoid becoming pregnant, and must agree to refrain from sexual activity or to use reliable contraceptive methods such as prescribed birth control or IUD for 24 hours following administration of [18F]FBB;
  • - are not able to give informed consent (personally or via authorized person) for whatever reason.

研究者

发起方
VU University Medical Center

相似试验

A diagnostic marker to visualize Alzheimer pathology... | 临床试验